Chugai deal positions Circadian as "dominant" player in VEGF-D rights
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary, Chugai, has granted the Australian bioventure Circadian exclusive worldwide rights to its intellectual property (IP) estate in the area of vascular endothelial growth factor D (VEGF-D).